Literature DB >> 10600597

Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.

M Ui1, T Kuwata, T Igarashi, K Ibuki, Y Miyazaki, I L Kozyrev, Y Enose, T Shimada, H Uesaka, H Yamamoto, T Miura, M Hayami.   

Abstract

To evaluate the potential of SHIVs as anti-HIV-1 live vaccines, we constructed two gene-deleted SHIVs, designated SHIV-drn and SHIV-dxrn. The former lacks vpr/nef and the latter lacks vpx/vpr/nef. Four macaques that had been vaccinated with SHIV-drn were challenged with SHIV-NM-3rN, which has an HIV-1 Env that is the same as that of SHIV-drn. No challenge virus was detected by DNA PCR in, or recovered from, two of the macaques. In the other two, challenge virus was detected once and twice, respectively. Plasma viral loads were much lower than those in unvaccinated controls. Another four macaques were vaccinated with SHIV-dxrn. These macaques showed resistance but less than that of SHIV-drn-vaccinated macaques. When the two SHIV-drn-vaccinated macaques were challenged with pathogenic SHIV-89.6P, which has an HIV-1 Env that is antigenically different from that of SHIV-drn, replication of the challenge virus was restricted, and the usual decrease in the number of CD4(+) cells was prevented. In this protection, it is noteworthy that protection involved not only neutralizing antibodies and killer cell activity, but also other unknown specific and nonspecific immunity elicited by the infection. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600597     DOI: 10.1006/viro.1999.0049

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Construction and characterization of chimeric BHIV (BIV/HIV-1) viruses carrying the bovine immunodeficiency virus gag gene.

Authors:  Yi-Xin Zhu; Chang Liu; Xin-Lei Liu; Wen-Tao Qiao; Qi-Min Chen; Yi Zeng; Yun-Qi Geng
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

3.  Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Authors:  Jodi K Craigo; Feng Li; Jonathan D Steckbeck; Shannon Durkin; Laryssa Howe; Sheila J Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.

Authors:  Mars Stone; Zhong-Min Ma; Meritxell Genescà; Linda Fritts; Shelley Blozois; Michael B McChesney; Christopher J Miller
Journal:  Virology       Date:  2009-08-03       Impact factor: 3.616

5.  A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.

Authors:  Feng Li; Jodi K Craigo; Laryssa Howe; Jonathan D Steckbeck; Sheila Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Increased Virus Replication and Cytotoxicity of Non-pathogenic Simian Human Immuno Deficiency Viruses-NM-3rN After Serial Passage in a Monkey-Derived Cell Line.

Authors:  Tb Kwofie; T Miura
Journal:  Ann Med Health Sci Res       Date:  2013-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.